Early and Target‑Driven Management of Rheumatoid Arthritis

Initial Treatment Strategy

The European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) recommend starting methotrexate (MTX) together with a short‑course of glucocorticoids immediately at rheumatoid arthritis (RA) diagnosis, reassessing disease activity at 3 months and escalating to a biologic DMARD (bDMARD) or targeted synthetic DMARD (tsDMARD) by 6 months if treatment targets are not met【1】.
DMARD therapy should be initiated as soon as RA is diagnosed because early treatment prevents irreversible joint damage【1】.
MTX is the anchor drug for the initial treatment strategy in most patients【3】.
Short‑term glucocorticoids should be added at treatment initiation (any approved dose or route) and tapered as rapidly as clinically feasible【1】.
If MTX is contraindicated or not tolerated, leflunomide or sulfasalazine may be used as alternative csDMARDs【1】.
Triple therapy (MTX or leflunomide + sulfasalazine + hydroxychloroquine) is an acceptable option, whereas hydroxychloroquine alone has limited efficacy【1】.

The primary goal is sustained clinical remission, with low disease activity (LDA) as an acceptable alternative【1】.
Validated composite scores (DAS28, SDAI, CDAI) endorsed by the ACR should be used for disease‑activity monitoring【5】.
Disease activity must be assessed every 1–3 months while the disease is active【1】.
If no improvement is seen by 3 months or the target is not reached by 6 months, therapy must be adjusted【1】.

Patients without poor prognostic factors may have another conventional synthetic DMARD (csDMARD) added or switched (e.g., leflunomide, sulfasalazine, or combinations)【1】.
Poor prognostic factors include:
- High‑titer rheumatoid factor (RF) or anti‑CCP antibodies【2】
- High disease activity【5】
- Early radiographic erosions【6】
- Failure of two csDMARDs【6】
In the presence of poor prognostic factors, add a bDMARD or tsDMARD to the csDMARD backbone【1】.
bDMARD options: TNF inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab ± biosimilars), abatacept, IL‑6 receptor inhibitors (tocilizumab, sarilumab), or rituximab after TNF‑inhibitor failure【1】.
tsDMARD options: Janus kinase (JAK) inhibitors (tofacitinib, baricitinib, filgotinib, upadacitinib)【1】.

If the first bDMARD or tsDMARD fails, switch to another bDMARD (different or same class) or to a tsDMARD【1】.
After failure of a single TNF inhibitor, clinicians may either switch to a different mechanism of action or try a second TNF inhibitor【3】.
All bDMARDs and tsDMARDs should be combined with a csDMARD for optimal efficacy【1】.
IL‑6 pathway inhibitors and JAK inhibitors may be used as monotherapy when a csDMARD cannot be co‑prescribed【1】.
Combination therapy (bDMARD or tsDMARD + MTX or another csDMARD) demonstrates superior efficacy compared with monotherapy【1】.
In MTX‑naïve patients, adding a bDMARD to MTX does not outperform MTX + glucocorticoids, supporting the stepwise approach【1】.
Starting MTX and adding a TNF inhibitor at 6 months if needed yields overall results comparable to initiating combination therapy from the outset【1】.

Patients must maintain remission or LDA for ≥ 6 months before any tapering is considered【5】.
Glucocorticoids are tapered first, followed by bDMARDs/tsDMARDs (especially when used with a csDMARD), and finally csDMARDs【1】.
DMARDs should be tapered rather than stopped completely; abrupt discontinuation raises the risk of disease flare【1】.
Dose reduction refers to lowering the dose or extending the dosing interval【5】.

Serious infection risk (requiring IV antibiotics or hospitalization) must be evaluated for all immunosuppressive therapies【5】.
Patient education about MTX is essential to dispel misconceptions that it is equivalent to high‑dose chemotherapy【1】.

Cost‑effectiveness should be incorporated from a societal perspective when selecting therapies【3】.
Biosimilars are regarded as clinically equivalent to originator bDMARDs and provide cost savings【5】.
The stepwise strategy (MTX first, biologics later) is cost‑effective because many patients achieve disease targets without expensive biologics【1】.

Do not delay DMARD initiation; waiting for diagnostic confirmation wastes the critical early treatment window【1】.
Do not continue ineffective therapy beyond 3–6 months, as prolonged active disease leads to irreversible damage【1】.
Do not rely on hydroxychloroquine monotherapy for typical RA; its efficacy is limited and it is reserved for very mild disease【1】.
Do not stop DMARDs completely once remission is achieved; taper gradually while maintaining some therapy to prevent flares【1】.